Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Cecilia P.Y. Lau"'
Autor:
Chi Hang Wong, Yan Li, Connie W.C. Hui, Cecilia P.Y. Lau, Margaret H.L. Ng, Brigette B.Y. Ma, Edwin P. Hui, Vivian Wai Yan Lui, S.W. Tsao, Anthony T.C. Chan
Publikováno v:
Investigational New Drugs. 31:567-575
Nasopharyngeal carcinoma (NPC) is endemic to Asia and over 40 % of NPC tissues harbor PIK3CA amplifications. This study characterized the preclinical activity of MK-2206, an oral allosteric inhibitor of AKT in 6 NPC cell lines: C666-1, HK1, HONE-1-EB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e1e2c102d282ccb284597251147685
https://doi.org/10.1007/s10637-012-9896-5
https://doi.org/10.1007/s10637-012-9896-5
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
Autor:
S. H. Cheng, Brigette B.Y. Ma, Patrick Kwok Shing Ng, Stephen Kwok-Wing Tsui, Cecilia P.Y. Lau, Sai Wai Tsao, Vivian Wai Yan Lui, Crystal S.F. Cheung, Edwin P. Hui, Kakiu Ho, Anthony T.C. Chan, Margaret H.L. Ng
Publikováno v:
Investigational New Drugs. 31:30-38
This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines. Selumetinib could achieve up to 90 % inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eba65e0e3448888f273f34680b3418d1
https://doi.org/10.1007/s10637-012-9828-4
https://doi.org/10.1007/s10637-012-9828-4
Autor:
Kakiu Ho, Margaret H.L. Ng, Brigette B.Y. Ma, Cecilia P.Y. Lau, Vivian Wai Yan Lui, Edwin P. Hui, Cesar Sze-chuen Wong, Crystal S.F. Cheung, Anthony T.C. Chan, Suk Hang Cheng
Publikováno v:
Investigational New Drugs. 29:1123-1131
Purpose: Sunitinib is a multi-target receptor tyrosine kinase (RTK) inhibitor against vascular endothelial growth factor receptors, platelet-derived growth factor receptors (PDGFR), c-kit and RET. Several of these RTKs are known to be involved in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d24276abb752252b76f965a6d6863d
https://doi.org/10.1007/s10637-010-9451-1
https://doi.org/10.1007/s10637-010-9451-1
Autor:
Anthony T.C. Chan, Brigette B.Y. Ma, Herbert H. Loong, Cecilia P.Y. Lau, Connie W.C. Hui, Edwin P. Hui, Chi Hang Wong
Publikováno v:
Investigational new drugs. 31(6)
Nasopharyngeal carcinoma (NPC) is common in Southeast Asia and over 40 % of NPC tissues have PIK3CA amplification. This study characterized the preclinical activity of a novel potent dual PI3K/mTOR inhibitor, PF-04691502, in five NPC cell lines: CNE-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43669fbbdeb285c3fc31055dbd4720aa
https://pubmed.ncbi.nlm.nih.gov/23975511
https://pubmed.ncbi.nlm.nih.gov/23975511
Autor:
S. H. Cheng, Brigette B.Y. Ma, Crystal S.F. Cheung, Cecilia P.Y. Lau, Connie W.C. Hui, Chi Man Tsang, Margaret H.L. Ng, Vivian Wai Yan Lui, Anthony T.C. Chan, Sai W. Tsao, Kakiu Ho, C.H. Wong, Edwin P. Hui
Publikováno v:
Cancer letters. 343(1)
The dual PI3K-mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6dcea542db000151cc7edf7ed14db41
https://pubmed.ncbi.nlm.nih.gov/24041865
https://pubmed.ncbi.nlm.nih.gov/24041865
Autor:
Anthony T.C. Chan, Winnie Yeo, Qian Zhou, Chi Hang Wong, Stephen L. Chan, Connie W.C. Hui, Brigette B.Y. Ma, Cecilia P.Y. Lau, Vivian Wai Yan Lui
Publikováno v:
Cancer chemotherapy and pharmacology. 71(6)
RAD001 targets at the mammalian target of rapamycin (mTOR), while TKI-258 is a potent tyrosine kinase inhibitor targeting at fibroblast growth factor receptor, vascular endothelial growth factor receptor, platelet-derived growth factor receptor and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406b598f05e88eddaac1367cf584e541
https://pubmed.ncbi.nlm.nih.gov/23546591
https://pubmed.ncbi.nlm.nih.gov/23546591
Autor:
Anthony T.C. Chan, Cecilia P.Y. Lau, Kakiu Ho, Vivian Wai Yan Lui, Sai Wah Tsao, Suk Hang Cheng, Brigette B.Y. Ma, Margaret H.L. Ng, Edwin P. Hui
Publikováno v:
Investigational new drugs. 28(4)
Phosphorylated (pi-) protein kinase B (AKT) is commonly expressed in nasopharyngeal carcinoma (NPC) cell lines and tissues, suggesting the involvement of AKT-mammalian target of rapamycin (mTOR) signaling in NPC carcinogenesis. This study evaluated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b72ea5fb06e77b9fdb4abd3d61b1985
https://pubmed.ncbi.nlm.nih.gov/19471857
https://pubmed.ncbi.nlm.nih.gov/19471857
Autor:
Brigette B.Y. Ma, Herbert H. Loong, Connie W.C. Hui, Cecilia P.Y. Lau, Eric C.H. Wong, Edwin P. Hui, Anthony T.C. Chan
Publikováno v:
Cancer Research. 73:2100-2100
Nasopharyngeal carcinoma (NPC) is common in Southeast Asia. PF-04691502 (PF) is a novel potent dual inhibitor of PI3K/mTOR capable of inhibiting downstream effectors Akt, S6 and 4E-BP1, resulting in suppression of protein synthesis and cell survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::620fc4c12ee8775382c969dbaafb515f
https://doi.org/10.1158/1538-7445.am2013-2100
https://doi.org/10.1158/1538-7445.am2013-2100
Autor:
Anthony T.C. Chan, Winnie Yeo, Chi Hang Wong, Cecilia P.Y. Lau, Vivian Wai Yan Lui, Connie W.C. Hui, Stephen L. Chan
Publikováno v:
Cancer Research. 72:2811-2811
Hepatocellular carcinoma (HCC) is one of the most lethal cancers. Signaling pathways including AKT-mTOR axis is often dysregulated in HCC. RAD001 principally targets at the mTOR complex 1. mTOR inhibition is reportedly associated with activation of f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e2ddc7dbfe6da0dc5b39958ae73f8f4
https://doi.org/10.1158/1538-7445.am2012-2811
https://doi.org/10.1158/1538-7445.am2012-2811